Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer
10.1097/CM9.0000000000002981
- VernacularTitle:Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer
- Author:
Lingling ZHU
1
;
Xianzhe YU
;
Xiaojun TANG
;
Chenggong HU
;
Lei WU
;
Yanyang LIU
;
Qinghua ZHOU
Author Information
1. Lung Cancer Center, Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
- Keywords:
Non-small cell lung cancer;
Liver metastasis;
Combination therapy;
Immune checkpoint inhibitors;
Immune tolerance;
Immunotherapy
- From:
Chinese Medical Journal
2024;137(9):1019-1032
- CountryChina
- Language:Chinese
-
Abstract:
Liver metastases (LMs) are common in lung cancer. Despite substantial advances in diagnosis and treatment, the survival rate of patients with LM remains low as the immune-suppressive microenvironment of the liver allows tumor cells to evade the immune system. The impact of LMs on the outcomes of immune checkpoint inhibitors in patients with solid tumors has been the main focus of recent translational and clinical research. Growing evidence indicates that the hepatic microenvironment delivers paracrine and autocrine signals from non-parenchymal and parenchymal cells. Overall, these microenvironments create pre- and post-metastatic conditions for the progression of LMs. Herein, we reviewed the epidemiology, physiology, pathology and immunology, of LMs associated with non-small cell lung cancer and the role and potential targets of the liver microenvironment in LM in each phase of metastasis. Additionally, we reviewed the current treatment strategies and challenges that should be overcome in preclinical and clinical investigations. These approaches target liver elements as the basis for future clinical trials, including combinatorial interventions reported to resolve hepatic immune suppression, such as immunotherapy plus chemotherapy, immunotherapy plus radiotherapy, immunotherapy plus anti-angiogenesis therapy, and surgical resection.
